Scale-up of HIV Treatment Through PEPFAR: A Historic Public Health Achievement : JAIDS Journal of Acquired Immune Deficiency Syndromes

Secondary Logo

Journal Logo

Supplement Article

Scale-up of HIV Treatment Through PEPFAR

A Historic Public Health Achievement

El-Sadr, Wafaa M. MD, MPH, MPA*; Holmes, Charles B. MD, MPH; Mugyenyi, Peter MD; Thirumurthy, Harsha PhD§; Ellerbrock, Tedd MD; Ferris, Robert DO, MPH; Sanne, Ian MD#; Asiimwe, Anita MD, MPH**; Hirnschall, Gottfried MD, MPH††; Nkambule, Rejoice N. MPH‡‡; Stabinski, Lara MD, MPH; Affrunti, Megan MSW, MPH*; Teasdale, Chloe MPH*; Zulu, Isaac MD§§; Whiteside, Alan DEcon‖‖

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes 60():p S96-S104, August 15, 2012. | DOI: 10.1097/QAI.0b013e31825eb27b
  • Free


The scale-up of HIV care and treatment services has led to the dramatic expansion of access to antiretroviral therapy (ART) for people living with HIV (PLWH) globally. As of the end of 2010, there were 6.6 million people who initiated ART in low- and middle-income countries (LMICs), compared with only 400,000 in 2003.1 The number of children receiving ART has risen from 71,500 in 2005 to 456,000 in 2010, with coverage of prevention of mother-to-child transmission (PMTCT) services rising to 48% from only 9% in 2004.1

One of the key driving forces behind this success has been the US President's Emergency Plan for AIDS Relief (PEPFAR), which was launched in 2003 by the US government to combat the global HIV/AIDS epidemic. The largest commitment by any nation to address a single disease in history, and the first global initiative to combat a chronic disease, PEPFAR's expansion of treatment access has been unparalleled for a global health and development initiative. As of September 2011, PEPFAR directly supported ART for 3.9 million men, women, and children worldwide and provided care and support to nearly 13 million.2 The PEPFAR approach is based on the following principles: (1) country ownership of local programs, (2) a result-based accountability approach, (3) engagement of all sectors, and (4) good governance. This article explores PEPFAR's approach to HIV treatment scale-up, key achievements, and opportunities and challenges for the future.


By reversing a tide of disease, fear, and societal disruption, especially in sub-Saharan Africa, where in some countries the HIV epidemic affected over one-quarter of adults, PEPFAR's treatment programs have had a stabilizing effect on health systems and communities. Despite initial concerns about the cost and feasibility of delivering ART for persons infected with and affected by HIV in challenging global settings with weak health systems, PEPFAR-supported national treatment programs have become a beacon of the global response to HIV for the past 8 years.

These programs have been developed and led by partner governments and supported by academic, nongovernmental, and faith-based organizations, along with US government agencies, including the Centers for Disease Control and Prevention (CDC), the Department of Defense, the Health Resources and Services Agency (HRSA), the Peace Corps, the US Agency for International Development (USAID), and more.3 They have also been built in a manner that has strengthened underlying health systems, through the renovation of clinical space, support for tiered laboratory networks, cross-training of health care providers, development of multi-commodity supply chain routes, and by encouraging general well-being through income generation activities and explicit support for strong community responses.

Although overall global budgets for HIV have leveled over the past several years, PEPFAR has maintained a strong focus on the expansion of HIV treatment services by leveraging and coordinating with other funders and through strategies to gain efficiency. For instance, in Tanzania, the government has used Global Fund to Fight AIDS, Tuberculosis and Malaria resources to procure first-line antiretroviral treatment, whereas PEPFAR has focused on strengthening regional and district health systems, training health care and public health management personnel, and providing support for innovation and quality improvement.4 PEPFAR has also pursued an efficiency agenda that has maximized the use of generic antiretroviral drugs (ARVs), supported efforts to enable nurses and other allied health professionals to provide treatment, and expanded use of financial information by program managers to decrease service delivery costs.5–7


An important factor that enabled the success of the scale-up of HIV treatment was the support by the World Health Organization (WHO) of a standardized and simplified treatment and patient-monitoring approach. Studies have shown that bringing services closer to where people live improves access and utilization and that decentralizing HIV treatment to primary facilities results in better patient retention and treatment adherence, contributes to reducing indirect costs of care for individuals and families, and also supports equity of care.8–10 However, in the face of the burden of HIV, LMICs face a shortage and maldistribution of human resources for health, particularly the concentration of health care workers in urban areas, a situation that threatens decentralization and hinders the scale-up of HIV treatment.

In 2008, WHO issued a global recommendation that proposed the adoption of a task-shifting approach to overcome shortages of human resources and rapid increase in access to HIV and other services.6 Task shifting signifies a rational distribution of tasks among cadres of health workers. Where appropriate, it implies that selected tasks are moved from highly qualified health workers to health workers with shorter training and fewer qualifications. Task shifting potentially saves time for highly specialized health workers to care for more complicated patients, whereas health workers with fewer qualifications provide care for stable patients, and lay workers do patient triage, education, and counselling.6,11,12

Several studies demonstrated the relevance of task shifting in different settings. A systematic review of studies in Africa, where HIV disease burden is high, indicated that task shifting is feasible and effective in expanding HIV treatment.6,13,14 Similar studies also show that task shifting results in comparable patient treatment outcomes and virological suppression.8,15 For example, in South Africa, based on evidence that nurse-monitored ART was not inferior to physician-monitored treatment, a shift to primary health care–based ART was undertaken.16 Further implementation research demonstrated that nurse-monitored ART was both cost-effective and led to improved treatment outcomes.17,18 With PEPFAR support, more than 20,000 nurses have been trained in both HIV and tuberculosis diagnosis and treatment, and nurse-initiated ART has become the norm. Thus, PEPFAR's adoption and support of task-shifting principles has enabled the expansion of HIV treatment in countries with some of the most severe health workforce constraints.19


Improved efficiency in selection and transportation of ARVs, the increasing use of generic drugs and fixed-dose combinations (FDCs), and the transition to preferred ARV regimens has lowered the cost of treatment substantially while improving the overall quality of HIV treatment in PEPFAR-supported focus countries. PEPFAR's per-patient treatment costs, including drugs and service delivery, have declined to $335 per year, from nearly $1100 just 7 years ago.20

One key improvement adopted by the Supply Chain Management System (SCMS), established and funded by PEPFAR and supported by the USAID, was the transition from air transport to land- or sea-based shipment.21 It is estimated that using sea freight for major shipments saved up to 85% in transportation costs, and as of December 31, 2010, sea transport had saved PEPFAR $39.8 million in transportation costs.21 SCMS also established regional distribution centers in Ghana, Kenya, and South Africa, increasing commodity availability and reducing the lead time needed for delivery.

PEPFAR has also increased its use of generic drugs and FDCs.7 In 2005, only 16% of PEPFAR-procured drugs were generic. This proportion increased to 97% in 2010, resulting in considerable savings compared with branded drugs (Fig. 1). Between 2008 and 2011 PEPFAR increased purchases of 2- and 3-drug FDCs, as recommended by the WHO (Fig. 2). These regimens are less complex, easier to administer, and may improve patient adherence. Similarly, over the past 4 years since WHO HIV treatment guidelines recommended that countries phase out stavudine in favor of less toxic zidovudine- or tenofovir-based regimens, SCMS orders for stavudine have declined by more than 70%, whereas orders for zidovudine and tenofovir have increased 20-fold (Fig. 3).

Box 1 Commitment to Local Partnerships

Number of generic versus branded drugs procured (monthly packs, 2005–2010). PEPFAR increased its use of generic drugs from 16% in 2005 to 97% in 2010.
Total SCMS orders for 2-and 3-drug ARVs. Between 2008 and 2011, PEPFAR increased its purchases of 2-and 3-drug FDCs, as recommended by WHO.
SCMS order quantity for zidovudine (AZT), stavudine (d4T), and tenofovir (TDF) in fiscal year (FY) 2008–2011. Since 2008, SCMS orders for stavudine have declined by more than 70%, whereas orders for zidovudine and tenofovir have increased 20-fold.


Scale-up of ART Access

The number of individuals receiving ART is one metric by which PEPFAR's achievement can be summarized. PEPFAR support increased the number of individuals who initiated ART from 66,700 to 3,905,500 (63% women and girls) from 2004 to 2011 (Fig. 4). During the first phase of PEPFAR, there was a rapid increase in the number of patients receiving ART, doubling each year between 2004 and 2007. In addition, during 2008–2011, PEPFAR increased the number of individuals receiving ART by more than 650,000 patients each year. Importantly, while the growth of PMTCT programs has likely reduced the number of infants newly infected with HIV each year, HIV-infected children comprise about 9% of those supported on treatment by PEPFAR, up from 7% earlier in the response. The treatment program's rapid expansion is also reflected in the increase in the number of health facilities providing ART, growing from 300 sites in 2004 to more than 6400 in 2009 (last year this indicator was reported centrally).

Number of adults and children with HIV infection receiving ART with direct PEPFAR support in fiscal year 2004–2011. PEPFAR support increased the number of individuals who initiated ART from 66,700 to 3,905,500.

Although the majority of treatment services are concentrated in 8 countries that collectively account for over half of the global HIV/AIDS epidemic, PEPFAR has supported treatment programs in more than 30 countries around the world26 through contributions to health system's strengthening in the form of policy developments, logistics, protocol or guideline development, advocacy, laboratory support, training, information systems, and capacity building of national HIV/AIDS programs. PEPFAR also has had a strong focus on ensuring quality of services and has used a variety of methods to monitor and ensure the quality of its programs,27 including sampled national survey studies28 and other methods, as described in more detail in an article in this journal issue.

Track 1.0 ART Program

One example that illustrates the rapid scale-up of ART while contributing substantially to health systems strengthening is the Track 1.0 ART Program. In September 2003, CDC and the HRSA published a request for applications (known as the Track 1.0 ART Program) with the goal to fund institutions with extensive HIV expertise to help initiate and support national HIV care and treatment programs in certain PEPFAR focus countries. Four organizations were selected for funding: AIDS Relief, a Catholic Relief Services Consortium, the Elizabeth Glaser Pediatric AIDS Foundation, ICAP at Columbia University, and the Harvard School of Public Health. Over the 8 years of the life of the program, the 4 partners received a total of $2.2 billion and were instrumental in the initiation of HIV care for 2.5 million and ART for 1.4 million HIV-infected adults and children at more than 1300 health facilities in 14 countries (Fig. 5). As of March 2011, the Track 1.0 ART Program was supporting more than 936,000 persons on ART, which provided for about 1 of 4 patients on ART supported by PEPFAR worldwide and about 1 of 6 persons on ART living in sub-Saharan Africa. Table 1 shows rapid expansion in funding for the program and of the portfolio and achievement of desired targets.

Track 1.0 ART Program Totals, by Program Year
Track 1.0 ART Program. Over the 8 years of the program, Track 1.0 ART partners were instrumental in initiating ART for 1.4 million HIV-infected adults and children.

Although initially focused on HIV treatment, over the years, the Track 1.0 ART Program funding has supported other HIV-related services, including PMTCT and integration of tuberculosis and HIV services. The Track 1.0 ART Program was also one of the first programs supported by PEPFAR that focused on strengthening existing health systems and local capacity and has successfully transitioned oversight and management of most programs to the Ministry of Health (MOH) and other indigenous organizations.

During 2011, CDC transitioned the oversight and management of the Track 1.0 ART Program from US-based partners to MOHs and other indigenous organizations for more than half of 1300 medical facilities in 13 countries that were providing ART for more than 925,000 patients.

Box 2 HIV Treatment in Times of Crisis

The Track 1.0 ART Program partners coordinated their efforts through the MOH; regional, provincial, and district government health offices; and faith-based organizations in each country. At the national level, the partners, working directly with MOH, helped develop and implement national HIV care and treatment guidelines; establish national laboratory, informatics, and SCMSs; prepare and support clinical and laboratory training courses; and participate in HIV technical workgroups. Support was also provided to regional, provincial, and district government health officers through subagreements to provide technical and infrastructure support. Extensive efforts were also provided at the health facility level, including clinical mentorship, hiring of additional staff, renovation of clinics and laboratories, purchasing of drugs and laboratory equipment and reagents, monitoring and evaluation, and support for community mobilization.

During 2011, CDC transitioned the oversight and management of the Track 1.0 Program from US-based partners to MOH and other indigenous organizations for more than half of 1300 medical facilities in 13 countries that were providing ART for more than 925,000 patients. Over the next 3 years, it is anticipated that the remaining facilities will be transitioned into host country national systems to help assure the sustainability of the programs in the future (Fig. 6).

ART Scale-up Saves Lives

As access to treatment has expanded, the number of AIDS-related deaths has declined substantially. In modeling of the epidemic both with and without ART, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that ART has averted 2.5 million deaths in LMICs since 1995 with the most deaths averted in sub-Saharan Africa, where approximately 1.8 million lives have been extended as a result of treatment.1 In sub-Saharan Africa, where AIDS-related deaths peaked in 2005 at 2.2 million, UNAIDS estimates that fewer people (460,000; 30%) died in 2010.

In a recent study that compared mortality in PEPFAR focus countries which were most severely affected with HIV/AIDS and received more PEPFAR resources in Africa versus non-focus countries, persons living in focus countries had 19.8% lower odds of death in the period from 2003 to 2008 when compared with those living in non-focus countries.29 Another analysis utilizing data from UNAIDS and from demographic health surveys from 2004 to 2007 showed a significant decrease in HIV- and AIDS-related deaths in PEPFAR focus countries after 4 years of implementation as compared with other African countries.30

Box 3 Achieving High ART Coverage—Rwanda

ART Scale-up and Social and Economic Outcomes

The deleterious impacts of HIV infection on individuals in terms of morbidity and mortality have been well documented since the disease first emerged. At the community and national levels, there were dire predictions of social, political, and economic collapse.41 Although these doomsday scenarios have fortunately been averted,30,42,43 empirical evidence on the economic impact of the HIV epidemic has also emerged. Significant declines in productivity of HIV-infected workers at tea plantations in Kenya was noted as early as 3 years before death.44 However, with expanded ART provision, rapid restoration of labor productivity has been noted. Research in rural Kenya demonstrated that employment outcomes improved within 6–12 months.45,46 More studies have shown similar individual-level economic benefits from ART provision.47 In South Africa, improvements in treated patients' employment outcomes have been shown to continue through the first 3 years on treatment48 and similar evidence has been shown in India.49 Renewed employment of an HIV-infected, working-age adult has had important consequences for household and community welfare as well. In Kenya, children living with adult ART recipients experience an increase in their school attendance and weight-for-height Z-scores, findings that are likely to lead to better economic outcomes for them in adulthood.50 Although HIV treatment alone is unlikely to transform the local and national economies of HIV-affected regions, wider provision of ART certainly promises to prevent further economic decline and to potentially restore socioeconomic well-being.


Access to HIV treatment worldwide has expanded substantially over the past decade with a significant reduction in AIDS-related morbidity and mortality.1 This achievement is the result of a global commitment and broad partnership between funders, country leadership and institutions, implementing organizations, and communities of people living with and affected by HIV.

Access to treatment has changed HIV disease from a “death sentence” into a manageable chronic condition for millions around the world. Yet, it is acknowledged that only 47% of PLWH in LMICs have access to such life-saving treatment and, thus, there is great urgency to expand HIV treatment programs. In addition, a number of recent scientific findings have changed the landscape for PEPFAR-supported treatment programs, including the results of the CIPRA Haiti 001 trial, which led WHO to recommend initiation of ART at a higher CD4+ cell count threshold (<350 cells/mm3), and the groundbreaking findings from HPTN 052, which demonstrated the efficacy of ART in reducing HIV transmission by 96% in HIV serodiscordant couples.51,52 These studies provided compelling scientific rationale for accelerating treatment access at earlier stages of HIV disease, not only for individual health benefits but also to help turn the tide of new infections. Model-based analyses have demonstrated that expanded treatment coverage, as part of a broader combination prevention package, could reduce annual new infections by more than 50% in the next 3 to 4 years.53

Key challenges remain to be addressed. Most PLWH are not aware of their HIV status, and in most settings, PLWH access ART at an advanced stage of HIV disease, contributing to mortality and morbidity and missed prevention opportunities.1,54 Furthermore, linkage from HIV testing to HIV prevention and care programs, retention in HIV care, timely initiation of ART upon eligibility, and achievement of high ART adherence rates remain key challenges in optimizing prevention and treatment outcomes for the individual, their partner, and the community.54 Continuing to address issues of ARV quality and cost in a proactive manner will also be essential to ensuring that PEPFAR investments result in the greatest possible impact on the HIV epidemic while building efficiencies that will foster greater sustainability and country ownership. This is particularly important in an era of resource constraints, although recent work has shown that in addition to the employment and productivity gains from ART, cost savings are garnered in the form of avoided expenditures on orphan care and delayed end-of-life care costs from AIDS-related morbidity.55 All in all, these findings suggest that from a societal perspective, the economic benefits are likely to equal or even exceed the costs of treatment provision, thereby indicating a positive economic return to investments in ART.50 Nevertheless, continuing to build a robust implementation research agenda will be fundamental to furthering the learning from ongoing programming and identifying efficient and effective methods to further expand the work and build on the success of PEPFAR.

In an address coinciding with the 2011 World AIDS Day, the compelling evidence for the remarkable gains achieved by expansion of HIV treatment and its potential impact on stemming the epidemic and enhancing the lives of communities around the world motivated US President Barack Obama to affirm the United States' leadership role in combating the global epidemic. He pledged to increase by 50% the number of people PEPFAR supports on treatment over the next 2 years. This strong commitment will ensure that PEPFAR continues to lead the world's response to the global HIV epidemic while serving as the foundation and platform for broader impacts through the US Global Health Initiative.


1. WHO. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. Geneva, Switzerland: HIV/AIDS Department, World Health Organization; 2011.
2. PEPFAR. Using Science to Save Lives: Latest PEPFAR Results. 2011. Available at: Accessed June 19, 2012.
3. Dybul M. Lessons learned from PEPFAR. J Acquir Immune Defic Syndr. 2009;52(suppl 1):S12–S13.
4. PEPFAR. Five year partnership framework in support of the Tanzanian national response to HIV and AIDS, 2009-2012 between the government of the United Republic of Tanzania and the Government of the United States of America. Available at: Accessed: June 19, 2012.
5. Office of the US Global AIDS Coordinator. PEPFAR: Making smart investments to increase impact and efficiency and save more lives. Available at: Accessed June 19, 2012.
6. WHO. Task Shifting: Global Recommendations and Guidelines. Geneva, Switzerland: WHO; 2008.
7. Holmes CB, Coggin W, Jamieson D, et al.. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA. 2010;304:313–320.
8. Jaffar S, Amuron B, Foster S, et al.. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009;374:2080–2089.
9. Veenstra N, Whiteside A, Lalloo D, et al.. Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these? Global Health. 2010;6:4.
10. O'Connor C, Osih R, Jaffer A. Loss to follow-up of stable antiretroviral therapy patients in a decentralized down-referral model of care in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2011;58:429–432.
11. Chung J, O'Brien M, Price J, et al.. Quantification of physician-time saved in a task shifting pilot program in Rwanda. Presented at: XVII International AIDS Conference, August 6, 2008. Vol Abstract #: WEAB0205, 2008; Mexico City, Mexico.
12. Torpey KE, Kabaso ME, Mutale LN, et al.. Adherence support workers: a way to address human resource constraints in antiretroviral treatment programs in the public health setting in Zambia. PLoS One. 2008;3:e2204.
13. Shumbusho F, van Griensven J, Lowrance D, et al.. Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in Rwanda. PLoS Med. 2009;6:e1000163.
14. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8.
15. Veenstra N, Whiteside A. Economic impact of HIV. Best Pract Res Clin Obstet Gynaecol. 2005;19:197–210.
16. Sanne I, Orrell C, Fox MP, et al.. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010;376:33–40.
17. Long L, Brennan A, Fox MP, et al.. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011;8:e1001055.
18. Brennan A, Long L, Maskew M, et al.. Outcomes of stable HIV-positive patients down-referred from doctor-managed ART clinics to nurse-managed primary health clinics for monitoring and treatment. AIDS. 2011;25:2027–2036.
19. Philips M, Zachariah R, Venis S. Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea. Lancet. 2008;371:682–684.
20. Menzies NA, Berruti AA, Berzon R, et al.. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011;25:1753–1760.
21. Jamieson D. Efficiency gains through smarter transportation and pooled procurement. Available at: Accessed March 1, 2012.
22. Right to Care. Right to Care Annual Report 2010. Johannesburg, South Africa; 2010.
    23. The AIDS Support Organization Web site. Available at: Accessed June 20, 2012.
      24. Joint Clinical Research Centre Web site. Available at: Accessed June 20, 2012.
        25. Pape JW, Rouzier V, Ford H, et al.. The GHESKIO field hospital and clinics after the earthquake in Haiti—dispatch 3 from Port-au-Prince. N Engl J Med. 2010;362:e34.
        26. Joint United Nations Program on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2010.
        27. Nash D, Elul B, Rabkin M, et al.. Strategies for more effective monitoring and evaluation systems in HIV programmatic scale-up in resource-limited settings: implications for health systems strengthening. J Acquir Immune Defic Syndr. 2009;52(suppl 1):S58–S62.
        28. Auld AF, Mbofana F, Shiraishi RW, et al.. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453.
        29. Bendavid E, Holmes C, Miller G.HIV international assistance and adult mortality: Africa. Presented at: Conference on the Retroviruses and Opportunistic Infections, abstract #85, March 7, 2012; Seattle, WA
        30. Bendavid E, Bhattacharya J. The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes. Ann Intern Med. 2009;150:688–695.
        31. Kiboneka A, Nyatia RJ, Nabiryo C, et al.. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201.
        32. El-Sadr WM, Lundgren JD, Neaton JD, et al.. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
        33. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22:237–247.
          34. Kenya. UNGASSoHAUCR. 2010.
            35. Vreeman RC, Nyandiko WM, Sang E, et al.. Impact of the Kenya post-election crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya. Confl Health. 2009;3:5.
              36. Yoder RB, Nyandiko WM, Vreeman RC, et al.. Long-term impact of the Kenya postelection crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya. J Acquir Immune Defic Syndr. 2012;59:199–206.
              37. PEPFAR. Partnership to Fight HIV/AIDS in Cote d'Ivoire. Available at: Accessed June 20, 2012.
                38. Goosby E. US Department of State. An update on PEPFAR in Cote d'Ivoire. Available at:
                  39. USAID. Haiti, HIV/AIDS and PEPFAR. Available at: Accessed June 20, 2012.
                    40. Goosby E. Building of What Works: U.S. HIV/AIDS Programs Forge Haiti Earthquake Response. US Department of State. 2011. Available at:
                      41. UN Security Council. UN Security Council Resolution 1308 (2000) on the Responsibility of the Security Council in the Maintenance of International Peace and Security: HIV/AIDS and International Peace-keeping Operations. New York, NY: United Nations; 2000.
                      42. de Waal A, Klot JF, Mahajan M, with Dana Huber and ASCI co-chairs Georg Frerks and Souleymane M'Boup. HIV/AIDS, Security and Conflict: New Realities, New Responses, AIDS', Security and Conflict Initiative. New York, NY: Social Science Research Council and Netherlands Institute of International Relations; 2010.
                      43. Regondi I, Whiteside A. Global development goals and the international HIV response: A chance for renewal. In: Wilkinson R, Hulme D, ed. The Millenium Development Goals and Beyond; Global Development after 2015. London and New York: Routledge; 2012.
                      44. Fox MP, Rosen S, MacLeod WB, et al.. The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health. 2004;9:318–324.
                      45. Thirumurthy H, Zivin JG, Goldstein M. The economic impact of AIDS treatment: labor supply in Western Kenya. J Hum Resour. 2008;43:511–552.
                      46. Larson BA, Fox MP, Rosen S, et al.. Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS. 2008;22:421–425.
                      47. Beard J, Feeley F, Rosen S. Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care. 2009;21:1343–1356.
                      48. Rosen S, Larson B, Brennan A, et al.. Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010;5:e12731.
                      49. Thirumurthy H, Jafri A, Srinivas G, et al.. Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study. AIDS. 2011;25:239–246.
                      50. Zivin JG, Thirumurthy H, Goldstein M. AIDS treatment and intrahousehold resource allocation: children's nutrition and schooling in Kenya. J Public Econ. 2009;93:1008–1015.
                      51. Severe P, Juste MA, Ambroise A, et al.. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265.
                      52. Cohen MS, Chen YQ, McCauley M, et al.. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
                      53. Schwartlander B, Stover J, Hallett T, et al.. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377:2031–2041.
                      54. Hermans S, van Leth F, Manabe Y, et al.. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. HIV Med. 2012;13:337–344.
                      55. Resch S, Korenromp E, Stover J, et al.. Economic returns to investment in AIDS treatment in low and middle income countries. PLoS One. 2011;6:e25310.
                      © 2012 Lippincott Williams & Wilkins, Inc.